Faculty
Nancy Bartlett.jpg

Nancy L. Bartlett, MD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Research Interests

  • Non-Hodgkin's lymphoma
  • Hodgkin's disease
  • Chronic lymphocytic leukemia

Contact

  • 314-362-5654 (tel)
  • 314-747-5123 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Manuscripts

  • Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma
    Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP
    Br J Haematol 2017 Apr 17; [Epub ahead of print]
  • Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
    Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP
    Lancet Haematol 2017 Apr;4(4):e176-e182
  • Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
    Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED
    Leuk Lymphoma 2017 Jul;58(7):1607-1616
  • NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic leukemia, version 1.2017
    Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H
    J Natl Compr Canc Netw 2017 Mar;15(3):293-311
  • Hodgkin lymphoma: current status and clinical trial recommendations
    Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL
    J Natl Cancer Inst 2016 Dec 31;109(4):djw249
  • Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma
    Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY
    Mol Ther 2017 Jan 4;25(1):285-295
  • Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: a teaching case
    Fischer-Valuck BW, Green O, Mazur T, Li H, Chundury A, Rao YJ, Bartlett NL, Mutic S, Huang J
    Pract Radiat Oncol 2017 Jan-Feb;7(1):e23-e26
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103
    Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD
    Blood 2016 Nov 24;128(21):2510-2516
  • NCCN guidelines insights: non-Hodgkin's lymphomas, version 3.2016
    Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P
    J Natl Compr Canc Netw 2016 Sep;14(9):1067-79
  • Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration
    Cheah CY, Brockelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA
    Am J Hematol 2016 Sep;91(9):894-9
  • Diffuse large B-cell lymphoma version 1.2016
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H
    J Natl Compr Canc Netw 2016 Feb;14(2):196-231
  • A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW
    Eur J Cancer 2016 Feb;54:11-7
  • US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816
    Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW
    J Clin Oncol 2016 Jun 10;34(17):2020-7
  • A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma
    Oak E, Bartlett NL
    Expert Opin Drug Saf 2016 Jun;15(6):875-82
  • Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227
    Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP
    J Clin Oncol 2016 May 10;34(14):1620-5
  • Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria
    Rashidi A, Oak E, Carson KR, Wagner-Johnston ND, Kreisel F, Bartlett NL
    Leuk Lymphoma 2016 May;57(5):1191-1193
  • Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome
    Nguyen TT, Frater JL, Klein J, Chen L, Bartlett NL, Foyil KV, Kreisel FH
    Appl Immunohistochem Mol Morphol 2016 Jul;24(6):383-391
  • Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
    Chen R, Allibone S, Bartlett NL, Brice P, Chen A, Pose K, Rich L, Bonthapally V, Garfin PM, Fanale M
    Onco Targets Ther 2016 Apr 6;9:2027-34
  • Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
    Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M
    HELIOS investigators

    Lancet Oncol 2016 Feb;17(2):200-11
  • A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma
    Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL
    Clin Cancer Res 2016 Mar 1;22(5):1059-66
  • The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas
    Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA
    Clin Cancer Res 2016 Feb 1;22(3):596-608
  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
    Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ
    RESONATE-2 Investigators

    N Engl J Med 2015 Dec 17;373(25):2425-2437
  • A young woman with blurred vision and distal paresthesias
    Kung NH, Bartlett NL, Yaseen NR, Van Stavern GP, Bucelli RC
    JAMA Neurol 2015 Dec 1;72(12):1519-1523
  • Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
    Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH
    Br J Haematol 2015 Nov;171(4):530-8
  • Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)
    Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD
    J Clin Oncol 2015 Nov 1;33(31):3635-40
  • Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
    Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG
    Leuk Lymphoma 2015 Sep;56(9):2569-78
  • Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort
    Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA
    Am J Hematol 2015 Sep;90(9):778-83
  • Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)
    Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, Friedberg JW, Bartlett NL
    Blood 2015 Aug 13;126(7):851-7
  • Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 Trial
    Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ
    J Clin Oncol 2015 Jun 10;33(17):1936-42
  • Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-Cell lymphoma and transformed mycosis fungoides: SWOG 1108
    Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW
    J Clin Oncol 2015 Jul 20;33(21):2399-2404
  • Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma
    Rashidi A, Oak E, Bartlett NL
    Blood 2015 May 21;125(21):3354-5
  • Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies
    Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK
    Leuk Lymphoma 2015 Apr;56(4):1151-3
  • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)
    Morrison VA, Jung SH, Johnson J, LaCasce A, Blum KA, Bartlett NL, Pitcher BN, Cheson BD
    Leuk Lymphoma 2015 Apr;56(4):958-64
  • Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
    Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL
    Blood 2015 Feb 26;125(9):1394-402
  • Transformed follicular lymphoma: is early autologous stem cell transplantation indicated in the modern era?
    Jackson AE, Liu J, Bartlett NL, Cashen AF
    Ann Hematol Oncol 2014;1(1): 1002
  • Brentuximab vedotin in the front-line treatment of patients with CD30 + peripheral T-cell lymphomas: results of a phase I study
    Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR
    J Clin Oncol 2014 Oct 1;32(28):3137-43
  • Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
    Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA
    Leuk Lymphoma 2014 Oct;55(10):2328-34
  • Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission
    Pingali SR, Jewell SW, Havlat L, Bast MA, Thompson JR, Eastwood DC, Bartlett NL, Armitage JO, Wagner-Johnston ND, Vose JM, Fenske TS
    Cancer 2014 Jul 15;120(14):2122-9
  • A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
    de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R
    J Hematol Oncol 2014 Jun 12;7(1):44
  • Active idiotypic vaccination versus control immunotherapy for follicular lymphoma
    Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr
    J Clin Oncol 2014 Jun 10;32(17):1797-803
  • High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis
    May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2014 Jun;55(6):1345-9
  • Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
    Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y
    Blood 2014 May 15;123(20):3095-100
  • Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
    Wang M, Popplewell LL, Collins RH Jr, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA
    Br J Haematol 2014 May;165(4):510-8
  • Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma
    Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL
    J Clin Oncol 2014 Mar 20;32(9):912-8
  • Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
    Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A
    J Hematol Oncol 2014 Mar 19;7(1):24
  • The role of body mass index in survival outcome for lymphoma patients: US intergroup experience
    Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS
    Ann Oncol 2014 Mar;25(3):669-74
  • CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma
    Klein JL, Nguyen TT, Bien-Willner GA, Chen L, Foyil KV, Bartlett NL, Duncavage EJ, Hassan A, Frater JL, Kreisel F
    Am J Clin Pathol 2014 Mar;141(3):381-7
  • Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers
    Wildes TM, Farrington L, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, Fenske TS
    Ther Adv Hematol 2014 Feb;5(1):3-12
  • Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary
    Nguyen TT, Kreisel FH, Frater JL, Bartlett NL
    J Clin Oncol 2013 Nov 20;31(33):e443-5
  • Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis
    Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum KA, Flowers CR, Leonard JP, Habermann TM, Bartlett NL
    J Clin Oncol 2013 Nov 10;31(32):4132-9
  • The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
    Smith SM, Schoder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD
    Leuk Lymphoma 2013 Jul;54(7):1405-10
  • Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
    Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH
    Leuk Lymphoma 2013 Feb;54(2):277-83
  • Limited-stage hodgkin lymphoma
    Bartlett NL
    Am Soc Clin Oncol Educ Book 2013;2013:374-80
  • Therapy in primary mediastinal B-cell lymphoma
    Cashen AF, Christian BA, Bartlett NL
    N Engl J Med 2013 Jul 18;369(3):282-3
  • Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
    Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF
    Blood 2013 May 2;121(18):3547-53
  • Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma
    Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD
    J Clin Oncol 2013 Feb 20;31(6):692-700
  • The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
    Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ
    Br J Haematol 2013 Apr;161(1):76-86
  • Assessment of cellular proliferation in tumors by PET using 18F-ISO-1
    Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, Wagner-Johnson N, Mach RH
    J Nucl Med 2013 Mar;54(3):350-7
  • Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
    Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ
    J Clin Oncol 2013 Feb 20;31(6):684-91
  • Solid, low-attenuation splenic lesions on computed tomography in patients with indolent lymphoma often signal transformation: a series of ten patients
    Welch JS, Foyil KV, Powers ML, Middleton WD, Bartlett NL
    Clin Lymphoma Myeloma Leuk 2012 Dec;12(6):452-4
  • Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
    Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD
    Blood 2012 Oct 18;120(16):3280-7
  • Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin
    Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR
    Leuk Lymphoma 2012 Nov;53(11):2283-6
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
    Kostakoglu L, Schoder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, Lacasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD
    Leuk Lymphoma 2012 Nov;53(11):2143-2150
  • Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma
    Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, Fu Q, Chang SH, Colditz GA
    J Clin Oncol 2012 Sep 10;30(26):3217-22
  • Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies
    Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A
    Oncologist 2012;17(8):1073-80
  • Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study
    Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA
    Clin Lymphoma Myeloma Leuk 2012 Aug;12(4):238-43
  • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R
    J Clin Oncol 2012 Jun 20;30(18):2183-9
  • Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A
    J Clin Oncol 2012 Jun 20;30(18):2190-6
  • A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
    Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S
    Cancer 2012 Jun 15;118(12):3128-34
  • Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma
    Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M
    Blood 2012 May 3;119(18):4115-22
  • A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies
    Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL
    Clin Cancer Res 2012 Jan 1;18(1):248-255
  • Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma
    Foyil KV, Kennedy DA, Grove LE, Bartlett NL, Cashen AF
    Leuk Lymphoma 2012 Mar;53(3):506-7
  • A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    Blood 2011 Nov 10;118(19):5119-25
  • Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, Dipersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation
    Nanua S, Bartlett NL, Hassan A, Robirds D, Branson J, Frater JL, Nguyen TT, Kreisel F
    J Clin Pathol 2011 Nov;64(11):1032-4
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET
    Straus DJ, Johnson JL, Lacasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schoder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD
    Blood 2011 May 19;117(20):5314-20
  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254
    Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, For The Cancer Leukemia Group B And Eastern Cooperative Oncology Group
    Leuk Lymphoma 2011 Apr;52(4):587-96
  • 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of International Harmonization Project interpretation
    Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL
    J Nucl Med 2011 Mar;52(3):386-92
  • Pralatrexate in patients With relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
    O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Jo Lechowicz M, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S
    J Clin Oncol 2011 Mar 20;29(9):1182-9
  • The present: optimizing therapy - too much or too little?
    Bartlett NL
    Hematology Am Soc Hematol Educ Program 2010;2010:108-14
  • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A
    N Engl J Med 2010 Nov 4;363(19):1812-21
  • Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc{gamma}RIIIa-158 V/F polymorphism
    Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL
    Ann Oncol 2010 Nov;21(11):2246-2254
  • Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study
    Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD
    Cancer 2010 Jan 1;116(1):106-114
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
    Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP
    J Clin Oncol 2009 Dec 20;27(36):6101-8
  • A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK
    Br J Haematol 2009 Jul;146(2):171-9
  • Protein losing enteropathy associated with follicular lymphoma of the small bowel
    Cashen AF, Rubin DC, Bartlett NL
    Am J Clin Oncol 2009 Apr;32(2):222-3
  • Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551
    Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA
    Cancer Chemother Pharmacol 2009 Apr;63(5):793-8
  • High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - A CALGB 59804 correlative study
    Lai R, Bartlett NL, Mackey JR, Jung SH, Johnson JL, Cook JR, Jones D, Cass CE, Young JD, Said J, Cheson B, Hsi ED
    Leuk Lymphoma 2008 Jun;49(6):1202-5
  • Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B
    Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD
    Br J Haematol 2008 Feb;140(3):313-9
  • A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
    Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, Bernstein SH, Bociek RG, Lorenz JM, Hart BW, Barton J
    Blood 2008 Feb 15;111(4):1848-54
  • Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206
    Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL
    Leuk Lymphoma 2007 Jul;48(7):1313-9
  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
    Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP
    Ann Oncol 2007 Jun;18(6):1071-9
  • Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906
    Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B
    Leuk Lymphoma 2006 Aug;47(8):1511-7
  • Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity
    Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR
    Leuk Res 2005 Nov;29(11):1253-7
  • Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA
    Cancer 2005 Oct 15;104(8):1661-7
  • Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy
    Bartlett NL
    Hematology Am Soc Hematol Educ Program 2005:245-51
  • Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
    Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C
    Clin Lymphoma 2004 Sep;5(2):98-101
  • Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
    Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White C
    Cancer Biother Radiopharm 2004 Aug;19(4):478-81
  • Barriers to clinical trial participation by older women with breast cancer
    Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ
    J Clin Oncol 2003 Jun 15;21(12):2268-75
  • Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
    Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ
    Blood 2003 Jun 1;101(11):4285-9
  • Radiation dosimetry results from a phase II trial of ibritumomab tiuxetan (Zevalin TM) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-Lopez AJ, Witzig TE, White CA
    Cancer Biother Radiopharm 2003 Apr;18(2):165-78
  • Interdigitating dendritic reticulum cell tumor of lymph nodes: Case report with differential diagnostic considerations
    Ylagan LR, Bartlett NL, Kraus M
    Diagn Cytopathol 2003 May;28(5):278-81
  • Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
    Fracasso PM, Blum KA, Tan BR, Fears CL, Bartlett NL, Arquette MA, Clark RS
    Cancer 2002 Nov 15;95(10):2223-9
  • Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials
    Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ
    Cancer 2002 Sep 1;95(5):989-96
  • Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA
    Blood 2002 Jun 15;99(12):4336-42
  • Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA
    J Clin Oncol 2002 May 15;20(10):2453-63
  • Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
    Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA
    J Clin Oncol 2002 Feb 1;20(3):630-7
  • Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854
    Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA
    Cancer 2001 Jul 15;92(2):207-17
  • Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR
    Crit Rev Oncol Hematol 2001 Jul-Aug;39(1-2):181-94
  • Cyclin D1 as an aid in the diagnosis of mantle cell lymphoma in skin biopsies: a case report
    Moody BR, Bartlett NL, George DW, Price CR, Breer WA, Rothschild Y, Kraus MD
    Am J Dermatopathol 2001 Oct;23(5):470-6
  • Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492
    Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P
    J Clin Oncol 2000 Mar;18(5):972-80
  • Primary gastric plasmacytoma: a rare cause of hypertrophic gastritis in an adolescent
    Goyal A, Langer JC, Zutter M, Swanson P, Kraus MD, Bartlett N, Shackelford GD, Longtine JA, Perlmutter DH
    J Pediatr Gastroenterol Nutr 1999 Oct;29(4):424-30
  • Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature
    Kraus MD, Jones D, Bartlett NL
    Am J Med 1999 Aug;107(2):169-76
  • Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation
    Kraus MD, Bartlett NL, Fleming MD, Dorfman DM
    Am J Surg Pathol 1998 Oct;22(10):1255-66
  • Bone marrow staging in patients with non-Hodgkin's lymphoma: is flow cytometry a useful test? [see comments]
    Naughton MJ, Hess JL, Zutter MM, Bartlett NL
    Cancer 1998 Mar 15;82(6):1154-9
  • Assessment of knowledge about cancer pain management by physicians in training
    Mortimer JE, Bartlett NL
    J Pain Symptom Manage 1997 Jul;14(1):21-8
  • Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report
    Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ
    J Clin Oncol 1995 May;13(5):1080-8
  • Follicular large-cell lymphoma: intermediate or low grade?
    Bartlett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ
    J Clin Oncol 1994 Jul;12(7):1349-57
  • Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
    Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI
    J Clin Oncol 1994 Apr;12(4):835-42
  • MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices
    Bartlett NL, Kwak LW, Horning SJ
    Cancer 1993 Jun 15;71(12):4034-42
  • Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis
    Fields JN, Kuske RR, Perez CA, Fineberg BB, Bartlett N
    Cancer 1989 Mar 15;63(6):1225-32
  • Inflammatory carcinoma of the breast: treatment results on 107 patients
    Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N
    Int J Radiat Oncol Biol Phys 1989 Aug;17(2):249-55